Clinical Trial Update: Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study assessing single-dose exposure of odanacatib in participants with moderate hepatic insufficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED | Results posted: 2017-10-27